Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Authors:
- Luc Y. DirixLDLuc Y. Dirix
- Istvan TakacsITIstvan Takacs
- Guy JerusalemGJGuy Jerusalem
- Petros NikolinakosPNPetros Nikolinakos
- Hendrik-Tobias ArkenauHAHendrik-Tobias Arkenau
- Andres Forero-TorresAFAndres Forero-Torres
- Ralph BocciaRBRalph Boccia
- Marc E. LippmanMLMarc E. Lippman
- Robert SomerRSRobert Somer
- Martin SmakalMSMartin Smakal
- Leisha A. EmensLELeisha A. Emens
- Borys HrinczenkoBHBorys Hrinczenko
Top Cited Papers
Open Access
- 23 October 2017
- journal article
- clinical trial
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 167 (3) , 671-686
Abstract
Purpose Agents targeting programmed death receptor 1 (PD-1) or its ligand (PD-L1) have shown antitumor activity in the treatment of metastatic breast cancer (MBC). The aim of this study was to assess the activity of avelumab, a PD-L1 inhibitor, in patients with MBC. Methods In a phase 1 trial (JAVELIN Solid Tumor; NCT01772004), patients with MBC refractory to or progressing after standard-of-care therapy received avelumab intravenously 10 mg/kg every 2 weeks. Tumors were assessed every 6 weeks by RECIST v1.1. Adverse events (AEs) were graded by NCI-CTCAE v4.0. Membrane PD-L1 expression was assessed by immunohistochemistry (Dako PD-L1 IHC 73-10 pharmDx). Results A total of 168 patients with MBC, including 58 patients with triple-negative breast cancer (TNBC), were treated with avelumab for 2–50 weeks and followed for 6–15 months. Patients were heavily pretreated with a median of three prior therapies for metastatic or locally advanced disease. Grade ≥ 3 treatment-related AEs occurred in 13.7% of patients, including two treatment-related deaths. The confirmed objective response rate (ORR) was 3.0% overall (one complete response and four partial responses) and 5.2% in patients with TNBC. A trend toward a higher ORR was seen in patients with PD-L1+ versus PD-L1− tumor-associated immune cells in the overall population (16.7% vs. 1.6%) and in the TNBC subgroup (22.2% vs. 2.6%). Conclusion Avelumab showed an acceptable safety profile and clinical activity in a subset of patients with MBC. PD-L1 expression in tumor-associated immune cells may be associated with a higher probability of clinical response to avelumab in MBC.Keywords
Funding Information
- Merck KGaA
- Pfizer
This publication has 34 references indexed in Scilit:
- In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast CarcinomasClinical Cancer Research, 2014
- PD-L1 Expression in Triple-Negative Breast CancerCancer Immunology Research, 2014
- Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agentsAnnals of Oncology, 2012
- A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinomaAnnals of Oncology, 2011
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Triple-Negative Breast Cancer: Clinical Features and Patterns of RecurrenceClinical Cancer Research, 2007
- Extending Survival with Chemotherapy in Metastatic Breast CancerThe Oncologist, 2005
- Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockadeProceedings of the National Academy of Sciences, 2002
- Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasionNature Medicine, 2002
- Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte ActivationJournal of Experimental Medicine, 2000